We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vascular Solutions, Inc. | NASDAQ:VASC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 56.00 | 55.95 | 57.50 | 0 | 01:00:00 |
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Minnesota
|
41-1859679
|
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification No.)
|
Large accelerated filer ☐
|
Accelerated filer ☒
|
Non-accelerated filer ☐
|
Smaller Reporting Company ☐
|
Page
|
|||
PART 1. FINANCIAL INFORMATION |
2
|
||
Item 1.
|
2
|
||
Consolidated Balance Sheets |
2
|
||
Consolidated Statements of Earnings |
3
|
||
Consolidated Statements of Comprehensive Earnings |
4
|
||
Consolidated Statements of Cash Flows |
5
|
||
6
|
|||
Item 2.
|
13
|
||
Item 3.
|
20
|
||
Item 4.
|
21
|
||
21
|
|||
Item 1.
|
21
|
||
Item 1A.
|
21
|
||
Item 2.
|
27
|
||
Item 3.
|
27
|
||
Item 4.
|
27
|
||
Item 5.
|
27
|
||
Item 6.
|
28
|
June 30, 2016
|
December 31, 2015
|
|||||||
(unaudited)
|
(see note)
|
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
35,008
|
$
|
41,491
|
||||
Accounts receivable, net of reserves of $345 and $360 in 2016 and 2015, respectively
|
21,815
|
19,121
|
||||||
Inventories
|
24,059
|
22,105
|
||||||
Prepaid expenses and other
|
3,940
|
4,361
|
||||||
Total current assets
|
84,822
|
87,078
|
||||||
Property, plant and equipment, net
|
39,103
|
34,508
|
||||||
Goodwill
|
10,062
|
10,045
|
||||||
Intangible assets and other, net
|
8,145
|
8,445
|
||||||
Deferred tax assets, net of liabilities
|
6,535
|
4,797
|
||||||
Total assets
|
$
|
148,667
|
$
|
144,873
|
||||
Liabilities and shareholders’ equity
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
6,203
|
$
|
5,830
|
||||
Accrued compensation
|
5,701
|
6,702
|
||||||
Accrued expenses
|
2,579
|
4,125
|
||||||
Total current liabilities
|
14,483
|
16,657
|
||||||
Long-term deferred tax liabilities
|
74
|
72
|
||||||
Total long-term liabilities
|
74
|
72
|
||||||
Shareholders’ equity:
|
||||||||
Common stock, $0.01 per share par value: Authorized shares – 40,000,000 Issued and outstanding shares – 17,491,977 – 2016; 17,386,853 – 2015
|
175
|
174
|
||||||
Additional paid-in capital
|
103,118
|
102,123
|
||||||
Other
|
(1,363
|
)
|
(1,186
|
)
|
||||
Accumulated earnings
|
32,180
|
27,033
|
||||||
Total shareholders’ equity
|
134,110
|
128,144
|
||||||
Total liabilities and shareholders’ equity
|
$
|
148,667
|
$
|
144,873
|
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
(unaudited)
|
(unaudited)
|
|||||||||||||||
Net revenue:
|
||||||||||||||||
Product revenue
|
$
|
41,063
|
$
|
37,398
|
$
|
80,305
|
$
|
71,839
|
||||||||
License, royalty and collaboration revenue
|
124
|
152
|
260
|
322
|
||||||||||||
Total revenue
|
41,187
|
37,550
|
80,565
|
72,161
|
||||||||||||
Product costs and operating expenses:
|
||||||||||||||||
Cost of goods sold
|
14,298
|
12,660
|
27,869
|
23,956
|
||||||||||||
Collaboration expenses
|
13
|
46
|
40
|
100
|
||||||||||||
Research and development
|
5,031
|
4,202
|
10,058
|
8,270
|
||||||||||||
Clinical and regulatory
|
2,153
|
1,605
|
4,150
|
3,086
|
||||||||||||
Sales and marketing
|
9,596
|
8,461
|
19,240
|
17,193
|
||||||||||||
General and administrative
|
2,839
|
4,129
|
12,438
|
8,907
|
||||||||||||
Medical device excise taxes
|
–
|
395
|
–
|
770
|
||||||||||||
Amortization of purchased technology and intangibles
|
404
|
404
|
808
|
808
|
||||||||||||
Total product costs and operating expenses
|
34,334
|
31,902
|
74,603
|
63,090
|
||||||||||||
Operating earnings
|
6,853
|
5,648
|
5,962
|
9,071
|
||||||||||||
Other earnings
|
32
|
14
|
48
|
42
|
||||||||||||
Earnings before income taxes
|
6,885
|
5,662
|
6,010
|
9,113
|
||||||||||||
Income tax expense
|
(1,482
|
)
|
(1,935
|
)
|
(863
|
)
|
(3,179
|
)
|
||||||||
Net earnings
|
$
|
5,403
|
$
|
3,727
|
$
|
5,147
|
$
|
5,934
|
||||||||
Net earnings per share – basic
|
$
|
0.31
|
$
|
0.22
|
$
|
0.30
|
$
|
0.35
|
||||||||
Net earnings per share – diluted
|
$
|
0.31
|
$
|
0.21
|
$
|
0.29
|
$
|
0.33
|
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
(unaudited)
|
(unaudited)
|
|||||||||||||||
Net earnings
|
$
|
5,403
|
$
|
3,727
|
$
|
5,147
|
$
|
5,934
|
||||||||
Other comprehensive earnings (loss), net of tax of $0: Foreign currency translation adjustments
|
(238
|
)
|
320
|
(177
|
)
|
(391
|
)
|
|||||||||
Comprehensive earnings
|
$
|
5,165
|
$
|
4,047
|
$
|
4,970
|
$
|
5,543
|
Six Months Ended
June 30,
|
||||||||
2016
|
2015
|
|||||||
(unaudited)
|
||||||||
Operating activities
|
||||||||
Net earnings
|
$
|
5,147
|
$
|
5,934
|
||||
Adjustments to reconcile net earnings to net cash provided by operating activities:
|
||||||||
Depreciation
|
2,473
|
2,122
|
||||||
Amortization
|
808
|
808
|
||||||
Stock-based compensation
|
2,638
|
2,382
|
||||||
Deferred taxes, net
|
(1,736
|
)
|
1,573
|
|||||
Tax benefit from stock-based awards
|
–
|
(360
|
)
|
|||||
Change in accounts receivable allowance
|
(15
|
)
|
120
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(2,678
|
)
|
(2,908
|
)
|
||||
Inventories
|
(1,981
|
)
|
(4,164
|
)
|
||||
Prepaid expenses and other
|
422
|
495
|
||||||
Accounts payable
|
370
|
1,173
|
||||||
Accrued expenses
|
(2,549
|
)
|
1,117
|
|||||
Net cash provided by operating activities
|
2,899
|
8,292
|
||||||
Investing activities
|
||||||||
Purchase of property and equipment
|
(7,062
|
)
|
(5,262
|
)
|
||||
Purchase of building and land
|
–
|
(2,748
|
)
|
|||||
Acquisition of licensing rights
|
(500
|
)
|
–
|
|||||
Net cash used in investing activities
|
(7,562
|
)
|
(8,010
|
)
|
||||
Financing activities
|
||||||||
Repurchase of common shares
|
(3,527
|
)
|
(2,276
|
)
|
||||
Tax benefit from stock-based awards
|
–
|
360
|
||||||
Proceeds from the exercise of stock options and sale of stock, net of expenses
|
1,885
|
1,041
|
||||||
Net cash used in financing activities
|
(1,642
|
)
|
(875
|
)
|
||||
Decrease in cash and cash equivalents
|
(6,305
|
)
|
(593
|
)
|
||||
Effect of exchange rate changes on cash and cash equivalents
|
(178
|
)
|
(29
|
)
|
||||
Cash and cash equivalents at beginning of period
|
41,491
|
36,461
|
||||||
Cash and cash equivalents at end of period
|
$
|
35,008
|
$
|
35,839
|
||||
Supplemental disclosure of cash flow
|
||||||||
Cash paid for taxes
|
$
|
1,424
|
$
|
964
|
(1)
|
Basis of Presentation
|
(2) | Net Earnings per Share |
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
Weighted average shares outstanding – basic
|
17,179,000
|
17,018,000
|
17,151,000
|
16,995,000
|
||||||||||||
Weighted average shares outstanding – diluted
|
17,656,000
|
17,996,000
|
17,624,000
|
17,946,000
|
(3)
|
Revenue Recognition
|
(4)
|
Inventories
|
June 30,
2016
|
December 31,
2015
|
|||||||
(dollars in thousands)
|
||||||||
Raw materials
|
$
|
12,173
|
$
|
10,760
|
||||
Work-in-process
|
1,661
|
1,789
|
||||||
Finished goods
|
10,225
|
9,556
|
||||||
$
|
24,059
|
$
|
22,105
|
(5)
|
Goodwill and Other Intangible Assets
|
Goodwill
|
Acquired
Intangibles
and other
|
|||||||
(dollars in thousands)
|
||||||||
Balance at December 31, 2015
|
$
|
10,045
|
$
|
8,445
|
||||
Acquisition of licensing rights
|
–
|
500
|
||||||
Amortization
|
–
|
(808
|
)
|
|||||
Foreign currency translation adjustments
|
17
|
8
|
||||||
Balance at June 30, 2016
|
$
|
10,062
|
$
|
8,145
|
(6)
|
Credit Risk and Allowance for Doubtful Accounts
|
(7)
|
Concentrations of Credit and Other Risks
|
(8)
|
Dependence on Key Suppliers
|
(9)
|
Commitments and Contingencies
|
(10)
|
Income Taxes
|
(11)
|
Recently Issued Accounting Pronouncements
|
(12)
|
Products and Services
|
Three months ended June 30,
|
|||||||||||||
2016
|
2015
|
||||||||||||
Product
|
Primary Market
|
Net
Revenue
|
Percent
Change
|
Net
Revenue
|
|||||||||
(dollars in thousands)
|
|||||||||||||
GuideLiner
®
catheters
|
Interventional cardiology
|
$
|
12,104
|
(1
|
%)
|
$
|
12,272
|
||||||
Micro-introducer kits
|
Interventional radiology
|
3,704
|
24
|
%
|
2,986
|
||||||||
Turnpike
®
catheters
|
Interventional cardiology
|
3,377
|
419
|
%
|
650
|
||||||||
Pronto
®
catheters
|
Interventional cardiology
|
3,297
|
(11
|
%)
|
3,724
|
Three months ended June 30,
|
|||||||||||||
2016
|
2015
|
||||||||||||
Product
|
Primary Market
|
Net
Revenue
|
Percent
Change
|
Net
Revenue
|
|||||||||
Vein catheter reprocessing
|
Phlebology
|
2,981
|
(2
|
%)
|
3,048
|
||||||||
Hemostatic patches
|
Interventional cardiology
|
2,897
|
(2
|
%)
|
2,949
|
||||||||
Radial access products
|
Interventional cardiology
|
2,261
|
21
|
%
|
1,873
|
||||||||
Langston
®
catheters
|
Interventional cardiology
|
1,966
|
16
|
%
|
1,689
|
Six months ended June 30,
|
|||||||||||||
2016
|
2015
|
||||||||||||
Product
|
Primary Market
|
Net
Revenue
|
Percent
Change
|
Net
Revenue
|
|||||||||
(dollars in thousands)
|
|||||||||||||
GuideLiner
catheters
|
Interventional cardiology
|
$
|
23,762
|
5
|
%
|
$
|
22,612
|
||||||
Micro-introducer kits
|
Interventional radiology
|
7,273
|
25
|
%
|
5,840
|
||||||||
Pronto catheters
|
Interventional cardiology
|
6,700
|
(17
|
%)
|
8,106
|
||||||||
Vein catheter reprocessing
|
Phlebology
|
5,970
|
4
|
%
|
5,760
|
||||||||
Hemostatic patches
|
Interventional cardiology
|
5,742
|
(4
|
%)
|
5,971
|
||||||||
Turnpike
catheters
|
Interventional cardiology
|
5,674
|
605
|
%
|
804
|
||||||||
Radial access products
|
Interventional cardiology
|
4,360
|
24
|
%
|
3,511
|
||||||||
Langston catheters
|
Interventional cardiology
|
3,848
|
18
|
%
|
3,268
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|||||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
Primary Market
|
Revenue
Percentage
|
Revenue
Percentage
|
Revenue
Percentage
|
Revenue
Percentage
|
||||||||||||
Interventional cardiology
|
75
|
%
|
73
|
%
|
75
|
%
|
73
|
%
|
||||||||
Phlebology
|
12
|
%
|
13
|
%
|
12
|
%
|
13
|
%
|
||||||||
Interventional radiology
|
9
|
%
|
10
|
%
|
9
|
%
|
10
|
%
|
||||||||
Electrophysiology
|
4
|
%
|
4
|
%
|
4
|
%
|
4
|
%
|
||||||||
100
|
%
|
100
|
%
|
100
|
%
|
100
|
%
|
· | The future regulatory approval of newly-developed products . Any new product that we develop must be approved by the Food and Drug Administration (FDA) in the United States and by similar regulatory bodies in other countries before it can be sold. The requirements for obtaining product approval have undergone change, and the FDA frequently implements changes to the product approval process. We monitor the changing regulatory landscape and modify our regulatory submissions as necessary to obtain product approvals. |
· | Successfully integrating acquired and distributed products and services into our existing operations . The acquisition of products, product distribution rights, and services complementary to our existing product portfolio and customer call points provides an additional business opportunity, but is dependent on the successful integration of the acquired or distributed products into our existing business structure. Since 2010, we have acquired or licensed more than 10 products and services. |
· | Managing intellectual property . The interventional medical device industry is characterized by numerous patent filings and litigation claims made to protect new and evolving product ideas. To maximize the profitability of new product ideas, we seek patent protection for those product design and method concepts which we believe have the potential to provide substantial product revenue. Managing intellectual property assets and claims is a significant challenge for our business. |
· | Managing greater government regulation and scrutiny. Our products and business activities are subject to rigorous regulation, including by the U.S. FDA, Department of Justice, and numerous other federal, state, and foreign governmental authorities. These authorities have been increasing scrutiny of our industry and enforcement actions related to companies in it. Managing compliance with existing and future regulation of our industry and fulfilling regulatory disclosure requirements is a significant challenge for our business. |
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2016
|
2015
|
2016
|
2015
|
|||||||||||||
Net revenue:
|
||||||||||||||||
Product revenue
|
100
|
%
|
100
|
%
|
100
|
%
|
100
|
%
|
||||||||
License, royalty and collaboration revenue
|
-
|
-
|
-
|
-
|
||||||||||||
Total revenue
|
100
|
%
|
100
|
%
|
100
|
%
|
100
|
%
|
||||||||
Product costs and operating expenses:
|
||||||||||||||||
Cost of goods sold
|
35
|
%
|
34
|
%
|
35
|
%
|
33
|
%
|
||||||||
Collaboration expenses
|
-
|
-
|
-
|
-
|
||||||||||||
Research and development
|
12
|
%
|
11
|
%
|
13
|
%
|
12
|
%
|
||||||||
Clinical and regulatory
|
5
|
%
|
4
|
%
|
5
|
%
|
4
|
%
|
||||||||
Sales and marketing
|
23
|
%
|
23
|
%
|
24
|
%
|
24
|
%
|
||||||||
General and administrative
|
7
|
%
|
11
|
%
|
15
|
%
|
12
|
%
|
||||||||
Medical device excise taxes
|
-
|
1
|
%
|
-
|
1
|
%
|
||||||||||
Amortization of purchased technology and intangibles
|
1
|
%
|
1
|
%
|
1
|
%
|
1
|
%
|
||||||||
Total product costs and operating expenses
|
83
|
%
|
85
|
%
|
93
|
%
|
87
|
%
|
||||||||
Operating earnings
|
17
|
%
|
15
|
%
|
7
|
%
|
13
|
%
|
||||||||
Other earnings
|
-
|
-
|
-
|
-
|
||||||||||||
Earnings before income taxes .
|
17
|
%
|
15
|
%
|
7
|
%
|
13
|
%
|
||||||||
Income tax expense
|
(4
|
%)
|
(5
|
%)
|
(1
|
%)
|
(5
|
%)
|
||||||||
Net earnings
|
13
|
%
|
10
|
%
|
6
|
%
|
8
|
%
|
% Change
|
||||
Volume of existing products and services sold (including sales of new versions of existing products and services)
|
6
|
%
|
||
Pricing of existing products and services sold
|
1
|
%
|
||
Revenue from new products or services, defined as products and services that had no revenue in the second quarter of 2015
|
3
|
%
|
||
10
|
%
|
% Change
|
||||
Volume of existing products and services sold (including sales of new versions of existing products and services)
|
10
|
%
|
||
Pricing of existing products and services sold
|
-
|
%
|
||
Revenue from new products or services, defined as products and services that had no revenue in the first six months of 2015
|
2
|
%
|
||
12
|
%
|
· | $9,330,000 was generated primarily as a result of our net income of $5,147,000, increased by depreciation and amortization expense of $3,281,000 and stock-based compensation expense of $2,638,000; and reduced by non-cash tax uses of $1,736,000. |
· | $6,416,000 was used as a result of the net change in operating assets and liabilities primarily due to: an increase of $2,678,000 in accounts receivable; a decrease of $2,179,000 in accounts payable and accruals as a result of our payments of legal expense accruals relating to the Short Kit litigation; an increase of $1,981,000 in overall inventory; and a decrease of $422,000 in prepaid expenses, primarily due to the decrease in taxes receivable. |
June 30,
2016
|
December 31,
2015
|
|||||||
Days Sales Outstanding
|
48
|
46
|
||||||
Days Inventory on Hand
|
154
|
157
|
Payments Due by Period
|
||||||||||||||||||||
Contractual Obligations
|
Total
|
Less than
1 year
|
1 - 3 years
|
3 - 5 years
|
More than
5 years
|
|||||||||||||||
(dollars in thousands)
|
||||||||||||||||||||
Facility operating leases
|
$
|
1,069
|
$
|
350
|
$
|
436
|
$
|
283
|
$
|
-
|
||||||||||
Product license rights
|
500
|
100
|
400
|
-
|
-
|
|||||||||||||||
Total
|
$
|
1,569
|
$
|
450
|
$
|
836
|
$
|
283
|
$
|
-
|
·
|
believe that our products or services offer benefits compared to the methodologies and/or devices that they are currently using;
|
·
|
use our products or services and obtain acceptable clinical outcomes;
|
·
|
believe that our products or services are worth the price that they will be asked to pay; and
|
·
|
be willing to commit the time and resources required to change their current methodology.
|
·
|
the level of sales of our products and services in our markets;
|
·
|
our ability to introduce new products or services and enhancements in a timely manner;
|
·
|
the demand for, and acceptance of, our products and services;
|
·
|
the success of our competition and the introduction of alternative products or services;
|
·
|
our ability to command favorable pricing for our products and services;
|
·
|
the growth of the market for our products and services;
|
·
|
the expansion and rate of success of our direct sales force in the United States and our independent distributors internationally;
|
·
|
actions relating to ongoing FDA compliance;
|
·
|
the effects of intellectual property disputes;
|
·
|
the effects of government investigations and enforcement actions;
|
·
|
the size and timing of orders from independent distributors or customers;
|
·
|
the attraction and retention of key personnel, particularly in sales and marketing, regulatory, manufacturing and research and development;
|
·
|
unanticipated delays or an inability to control costs;
|
·
|
general economic conditions, as well as those specific to our customers and markets; and
|
·
|
seasonal fluctuations in revenue due to the elective nature of some procedures.
|
Ÿ
|
better name recognition;
|
Ÿ
|
broader product lines;
|
Ÿ
|
greater sales, marketing and distribution capabilities;
|
Ÿ
|
significantly greater financial resources;
|
Ÿ
|
larger research and development staffs and facilities; and
|
Ÿ
|
existing relationships with some of our potential customers.
|
·
|
the ability of our independent distributors to sell our products and services;
|
·
|
the impact of recessions or other disruptions in economies outside the United States, including from Great Britain’s exit from the European Union;
|
·
|
greater difficulty in collecting accounts receivable and longer collection periods;
|
·
|
unexpected changes in regulatory requirements, tariffs or other trade barriers;
|
·
|
weaker intellectual property rights protection in some countries;
|
·
|
potentially adverse tax consequences; and
|
·
|
political and economic instability.
|
·
|
obtain the clearance of the FDA and international agencies before we can market and sell our products and services;
|
·
|
satisfy these agencies’ content requirements for all of our labeling, sales and promotional materials; and
|
·
|
undergo rigorous inspections by these agencies.
|
Period
|
Total Number
of Shares
Purchased (1)
|
Average
Price Paid
per Share
|
Total Number of
Shares Purchased
as Part of a Publicly
Announced Plans or
Programs
|
Maximum Value of
Shares that May Yet be
Purchased Under the
Plans or Programs (2)
|
||||||||||||
April 1 – 30, 2016
|
-
|
-
|
-
|
$
|
17,372,009
|
|||||||||||
May 1 – 31, 2016
|
5,236
|
$
|
35.05
|
-
|
$
|
17,372,009
|
||||||||||
June 1 – 30, 2016
|
-
|
-
|
-
|
$
|
17,372,009
|
|||||||||||
Total
|
5,236
|
$
|
35.05
|
-
|
$
|
17,372,009
|
Exhibit
Number
|
Description
|
|
3.1
|
Amended and Restated Articles of Incorporation of Vascular Solutions, Inc. (incorporated by reference to Exhibit 3.1 to Vascular Solutions’ Form 10-Q for the quarter ended March 31, 2000 (File No. 0-27605)).
|
|
3.2
|
Amended and Restated Bylaws of Vascular Solutions, Inc. (incorporated by reference to Exhibit 3.1 of Vascular Solutions’ Form 8-K dated October 19, 2007 (File No. 0-27605)).
|
|
4.1
|
Specimen of Common Stock certificate (incorporated by reference to Exhibit 4.1 of Vascular Solutions’ Registration Statement on Form S-1 (File No. 333-84089)).
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
101.INS
|
XBRL Instance Document
|
|
101.SCH
|
XBRL Taxonomy Extension Schema
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase
|
VASCULAR SOLUTIONS, INC.
|
|||
Date: July 25, 2016
|
By:
|
/s/ Howard Root
|
|
Howard Root
|
|||
Chief Executive Officer and Director
|
|||
(
principal executive officer
)
|
|||
By:
|
/s/ James Hennen
|
||
James Hennen
|
|||
Senior Vice President of Finance and
|
|||
Chief Financial Officer
|
|||
(principal financial officer)
|
|||
By:
|
/s/ Timothy Slayton
|
||
Timothy Slayton
|
|||
Controller
|
|||
(principal accounting officer)
|
1 Year Vascular Solutions, Inc. Chart |
1 Month Vascular Solutions, Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions